BiosimilarBiological
PF-05280014 clinical trials
Also written PF-05280014.
A product of Trastuzumab; its studies count on that page too.
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
4 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses PF-05280014 is read from its arms, and is right about nine times in ten.
Testing it · 4
- A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)CompletedPhase 3PfizerNCT01989676Written as PF-05280014
- A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)CompletedPhase 3PfizerNCT02187744Written as PF-05280014
- A Study Evaluating The Safety Of PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-06)CompletedPhase 1PfizerNCT02015156Written as PF-05280014
- A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)CompletedPhase 1PfizerNCT01603264Written as PF-05280014